Related Experiment Video
Updated: Apr 28, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Exploring aigialomycin d and its analogues as protein kinase inhibitors for cancer targets
Jin Xu1, Anqi Chen2, Mei-Lin Go3
1Institute of Chemical and Engineering Sciences (ICES), Agency for Science, Technology and Research (ASTAR) , 8 Biomedical Grove, Neuros #07-01, Singapore 138665 ; Department of Pharmacy, National University of Singapore , 18 Science Drive 4, Singapore 117543.
Abstract:
The natural product aigialomycin D (1) is a member of the resorcylic acid lactone (RAL) family possessing protein kinase inhibitory activities. This paper describes the synthesis of aigialomycin D and a series of its analogues and their activity for the inhibition of protein kinases related to cancer pathways. A preliminary study of these compounds in the inhibition of CDK2/cyclin A kinase has found that aigialomycin D and analogues 11 and 23 are moderate CDK2/cyclin A inhibitors with IC50 values of ca. 20 μM. Kinase profiling of aigialomycin D against a panel of kinases has led to the identification of MNK2 as a promising target (IC50 = 0.45 μM), and preliminary structure-activity relationship studies have been carried out to identify the essential functional groups for activity.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle

